Journal article

Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals

Gail V Matthews, Eric Seaberg, Gregory J Dore, Scott Bowden, Sharon R Lewin, Joe Sasadeusz, Pip Marks, Zachary Goodman, Frances H Philp, Yiwei Tang, Stephen Locarnini, Chloe L Thio

AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2009

Abstract

OBJECTIVES: To determine if highly active antiretroviral therapy (HAART) with combination anti-hepatitis B virus (HBV) therapy compared to HAART with HBV monotherapy leads to greater HBV DNA suppression in an HIV/HBV coinfected cohort. DESIGN: A cross-sectional analysis of 122 HIV/HBV coinfected patients from Australia and the United States. METHODS: Univariate analysis and ordinal logistic regression were used to determine factors associated with an HBV DNA less than 100 IU/ml. RESULTS: The majority of patients were on HAART (85%), had an HIV RNA less than 50 copies/ml, a median CD4 cell count of 438 cells/microl, and had prior or current lamivudine therapy (98%). The majority (89%) of thos..

View full abstract

Grants

Awarded by National Institutes of Health (N.I.H.), USA


Awarded by National Heart, Lung and Blood Institute


Awarded by NATIONAL CENTER FOR RESEARCH RESOURCES


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Funding Acknowledgements

The study is funded by the National Institutes of Health (N.I.H.), USA R01AI060449. NCHECR is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, The University of New South Wales. Data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins University Bloomberg School of Public Health (Joseph B. Margolick, Lisa Jacobson), Howard Brown Health Center and Northwestern University Medical School (John Phair), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute and the National Heart, Lung and Blood Institute. UOI-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-Al-35043, UO1-AI-37984, UO1-Al35039, UO1-AI-35040, UO1-AI-37613, UO1-AI35041. Website located at http://www.statepi.jhsph.edu/inacs/macs.html. The authors wish to acknowledge the study participants and research staff at all sites who contributed to this study. In particular, the authors wish to acknowledge Professor Jenny Hoy from the Alfred Hospital, Melbourne and Dr Robert Finlayson at Taylor Square Private Clinic ill Sydney, who supervised the recruitment and conduct of the study at their respective study sites.